Long-term observation of renal function on combination therapy with prostaglandin and angiotensin-converting enzyme inhibitor for chronic kidney disease

Clinical Nephrology

Volumn 69, Issue 6, 2008, Pages 402-407

  Nakayama, Y ^a   Inoue, T ^a   Kohda, Y ^a   Inoue, H ^a   Izumi, Y ^a   Tomita, K ^a   Nonoguchi, H ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Angiotensin; Converting enzyme inhibitor; Prostaglandin; Renal survival

Indexed keywords

ALACEPRIL; BENAZEPRIL; CILAZAPRIL; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IMIDAPRIL; LIMAPROST; LIMAPROST ALFADEX; LISINOPRIL; PROSTAGLANDIN E1;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; FOLLOW UP; HEART PALPITATION; HUMAN; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PROTEINURIA; RENAL REPLACEMENT THERAPY; SURVIVAL RATE;

EID: 44949251866     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP69402     Document Type: Article

References (18)

1. Brenner BM. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int. 1983; 23: 647-655.
2. Gerber JG, Keller RT, Nies AS. Prostaglandins and renin release: the effect of PGI2, PGE2, and 13,14-dihydro PGE2 on the baroreceptor mechanism of renin release in the dog. Circ Res. 1979; 44: 796-799.
3. Ito S, Carretero OA, Abe K, Beierwaltes WH, Yoshinaga K. Effect of prostanoids on renin release from rabbit afferent arterioles with and without macula densa. Kidney Int. 1989; 35: 1138-1144.
4. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med. 1994; 330: 877-884.
5. Koch JA, Plum J, Grabensee B, Modder U. Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE1 Study Group. Nephrol Dial Transplant. 2000; 15: 43-49.
6. Levenson DJ, Simmons CE Jr, Brenner BM. Arachidonic acid metabolism, prostaglandins and the kidney. Am J Med. 1982; 72: 354-374.
7. Lianos EA. Biosynthesis and role of arachidonic acid metabolites in glomerulonephritis. Nephron. 1984; 37: 73-77.
8. Lin CY. Improvement in steroid and immunosuppressive drug-resistant lupus nephritis by intravenous prostaglandin E1 therapy. Nephron. 1990; 55: 258-264.
9. Moran M, Mazes MF, Maddux MS, Veremis S, Bartkus C, Ketel B, Pollak R, Wallemark C, Jonasson O. Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. N Engl J Med. 1990; 322: 1183-1188.
10. Nagao T, Nagamatsu T, Suzuki Y. Effect of lipoprostaglandin E1 on crescentic-type antiglomerular basement membrane nephritis in rats. Eur J Pharmacol. 1998; 348: 37-44.
11. Nakayama Y, Nonoguchi H, Kiyama S, Kohda Y, Inoue T, Tomita K. Long-term renoprotective effect of combination therapy with prostaglandin E1 and angiotensin-converting enzyme inhibitor in patients with chronic renal failure. Hypertens Res. 2005; 28: 733-739.
12. Niwa T, Maeda K, Naotsuka Y, Asada H, Kobayashi S, Yokohama M, Kawaguchi S, Shibata M. Improvement of renal function with prostaglandin E1 infusion in patients with chronic renal disease. Lancet. 1982; 1: 687.
13. 2+ via enhanced prostaglandin E2. J Clin Invest. 1989; 84: 1866-1872.
14. Perinotto P, Biggi A, Carra N, Orrico A, Valmadre G, Dall'Aglio P, Novarini A, Montanari A. Angiotensin II and prostaglandin interactions on systemic and renal effects of L-NAME in humans. J Am Soc Nephrol. 2001; 12: 1706-1712.
15. Sakai A, Yajima M, Nishio S. Cytoprotective effect of TRK-100, a prostacyclin analogue, against chemical injuries in cultured human vascular endothelial cells. Life Sci. 1990; 47: 711-719.
16. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet. 1997; 349: 1857-1863.
17. Torsello G, Schror K, Szabo Z, Kutkuhn B, Strobach H, Godehardt E, Sandmann W. Effects of prostaglandin E1 (PGE1) on experimental renal ischaemia. Eur J Vasc Surg. 1989; 3: 5-13.
18. Utsunomiya Y. Ogura M, Kawamura T, Mitarai T, Maruyama N, Sakai O. Attenuation of immune complex nephritis in NZB/WF1 mice by a prostacyclin analogue. Clin Exp Immunol. 1995; 99: 454-460.